Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
0R19 LN​

Becton Dickinson & Co(0R19 LN)

$199.04+1.040.53%(Market Closed · 17:49:52 UTC · (15 min delay))

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingEmployees

Becton Dickinson & Co — Company Profile

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
LN
CEO
Thomas E. Polen Jr.
Headquarters
Franklin Lakes, NJ, US
IPO Date
Nov 5, 2014
Employees
72,000
Website
www.bd.com

Key Metrics

Price
$176.96
Market Cap
$50.44B
Revenue (TTM)
$4.71B
Net Income (TTM)
$-311000000.00
EPS (TTM)
-1.11
P/E (TTM)
44.32
P/B (TTM)
2.09
Dividend Yield
33.42%
ROE (TTM)
-1.29%
ROA (TTM)
-0.61%
Operating Margin
13.28%
Beta
0.59

Dividends

Last Dividend
$1.05
Last Yield
0.33%

Summary

Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.

Website
www.bd.com
Location
Franklin Lakes, NJ, US
Phone201 847 6800
Employees72,000
CEOThomas E. Polen Jr.
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateNov 5, 2014

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(3K)

Expand
  • 4Statement of changes in beneficial ownership29 Sep
  • 144Feld Michael28 Sep
  • 4Statement of changes in beneficial ownership3 Sep
  • 4Statement of changes in beneficial ownership27 Aug
  • 144Feld Michael26 Aug
  • 4Statement of changes in beneficial ownership24 Aug
  • 144Byrd Richard20 Aug
  • 4Statement of changes in beneficial ownership14 Aug
  • 144Polen Thomas E Jr13 Aug
  • 4Statement of changes in beneficial ownership12 Aug
  • 144Goette Roland11 Aug
  • SC 13GBECTON DICKINSON & CO7 Aug
  • 4Statement of changes in beneficial ownership6 Aug
  • 4Statement of changes in beneficial ownership6 Aug
  • 10-QQ3ended 30 Jun 20266 Aug
  • SC 13GBECTON DICKINSON & CO6 Aug
  • 8-KResults of Operations and Financial Condition6 Aug
  • 144Neal Shana Carol3 Aug
  • 4Statement of changes in beneficial ownership28 Jul
  • 144Feld Michael27 Jul

Mentions in Filings

  • … opharmaceutical company, and PMV Pharmaceuticals, Inc., a precision oncology company. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and <strong>Becton, Dickinson and Company</strong>. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a …
    Aspen Neuroscience, Inc.Becton Dickinson & Co·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … opharmaceutical company, and PMV Pharmaceuticals, Inc., a precision oncology company. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and <strong>Becton, Dickinson and Company</strong>. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a …
    Aspen Neuroscience, Inc.Becton Dickinson & Co·S-1 - Registration statement (general form)·Q4 26·9 Oct
  • On March 31, 2024, the Company and Bard’s parent company <strong>Becton, Dickinson and Company</strong> (collectively, “BD”) entered into a settlement agreement (the “Settlement Agreement”) to resolve the ongoing litigations. Neither party admitted any liability and the Settlement Agreement contains mutual covenants not to sue and releases. Under the terms of the Settlement Agreement, BD granted a license to the Company under certain of BD’s port patents and Angi …
    ANGIODYNAMICS INCBecton Dickinson & Co·10-Q - Quarterly report Q1·Q1 27·8 Oct
  • … | 3,423 | | TROW | T. Rowe Price Group, Inc. | | 2.03% | | 36 | | 100.10 | | 3,604 | | WRB | W.R. Berkley Corporation | | 2.04% | | 49 | | 74.08 | | 3,630 | | Health Care (10.16%): | | | | | | | | | | | BDX | <strong>Becton, Dickinson and Company</strong> | | 2.04% | | 19 | | 190.74 | | 3,624 | | MDT | Medtronic Plc † | | 2.03% | | 39 | | 92.77 | | 3,618 | | RMD | ResMed Inc. | | 2.02% | | 15 | | 239.77 | | 3,596 | | SYK | Stryker Corporation | | 2.01% | | 12 | …
    FT 13302Becton Dickinson & Co·487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·20 Oct
  • … Corporation \* | | 0.10% | | 13 | | 115.48 | | 1,501 | | AMLX | Amylyx Pharmaceuticals, Inc. \* | | 0.10% | | 56 | | 27.48 | | 1,539 | | AZN | AstraZeneca Plc † | | 0.40% | | 39 | | 158.33 | | 6,175 | | BDX | <strong>Becton, Dickinson and Company</strong> | | 0.50% | | 41 | | 188.89 | | 7,744 | | BSX | Boston Scientific Corporation \* | | 0.50% | | 177 | | 43.84 | | 7,760 | | CAH | Cardinal Health, Inc. | | 0.51% | | 33 | | 238.08 | | 7,857 | | COR | Cencora, In …
    FT 13273Becton Dickinson & Co·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct
  • … Corporation \* | | 0.07% | | 10 | | 115.48 | | 1,155 | | AMLX | Amylyx Pharmaceuticals, Inc. \* | | 0.07% | | 40 | | 27.48 | | 1,099 | | AZN | AstraZeneca Plc † | | 0.27% | | 28 | | 158.33 | | 4,433 | | BDX | <strong>Becton, Dickinson and Company</strong> | | 0.33% | | 29 | | 188.89 | | 5,478 | | BSX | Boston Scientific Corporation \* | | 0.33% | | 127 | | 43.84 | | 5,568 | | CAH | Cardinal Health, Inc. | | 0.33% | | 23 | | 238.08 | | 5,476 | | COR | Cencora, In …
    FT 13272Becton Dickinson & Co·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct

Key Stats

Trading

Px/Chg 1D$176.96 / +0.28%
Avg Volume1.24K
Beta0.59
Mkt Cap50.44B
FD Mkt Cap53.98B

Float

Shrs Out/Float285.01M / 274.69M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$2.00B

Current Valuation

EV66.70B
EV/EBITDA12.63
EV/Sales3.12
P/B2.09
P/S2.36
FCF Yield0.94%
ROE-1.29%
ROA-0.61%
Current Ratio0.94

Dividend

Cash$1.05
Yield33.42%
Yield (TTM)33.42%

Estimates

P/E44.32
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgDec '22Dec '23Dec '24Dec '25Oct '26
PRICE-BASED RATIOS
Price / Earnings15.6041.2946.8838.63113.37-162.17
Price / Sales6.193.893.593.269.4910.70
Price / Book Value2.492.912.702.542.202.09
Price / Free Cash Flow52.1944.2232.8921.4355.78106.63
ENTERPRISE VALUE METRICS
Enterprise Value79,883.688,867.284,557.785,073.974,219.366,699.8
Enterprise Value / Sales8.014.714.364.2212.6014.15
Enterprise Value / EBITDA34.0720.7319.7818.1957.3654.27
Enterprise Value / EBIT66.4840.6740.0033.59111.61106.55

Financials

Full Financials
Millions USD5Yr CAGR (%)Sep '21Sep '22Sep '23Sep '24Sep '25
INCOME STATEMENT
Revenue3.4%19,131.018,870.019,372.020,178.021,839.0
Gross Income3.6%8,631.08,477.08,823.09,125.09,924.0
EBITDA3.9%4,252.04,287.04,275.04,677.04,957.0
EBIT3.7%2,161.02,185.02,114.02,533.02,495.0
Net Income-5.4%2,092.01,779.01,484.01,705.01,678.0
EPS (Diluted)-4%6.855.885.105.865.83
BALANCE SHEET
Cash & ST Inv-22.7%2,404.01,167.01,424.02,301.0859.0
Total Assets67%53,866.052,934.052,780.057,286.055,325.0
Total Liabilities-21%30,189.027,652.026,984.031,396.029,936.0
Total Shareholder Equity1.8%23,677.025,282.025,796.025,890.025,390.0
CASH FLOW
Net Operating Cash Flow-7.3%4,647.02,634.02,989.03,798.03,430.0
Cap Ex-10.7%-1,194.0-973.0-874.0-725.0-760.0
Free Cash Flow-6.2%3,453.01,661.02,115.03,073.02,670.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)196.57
Basic Shares285.01
Market Cap56,024.9
Diluted Shares280.64
Fully Diluted Shares Outstanding280.64
Fully Diluted Market Cap55,165.4
+Consolidated Debt17,279.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,015.0
−Short-term Investments-3.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value72,288.9

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

L3harris Technologies, Inc. /DE/

LHX US